Form 4 for ANIK Anika Therapeutics, Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-14 · accession 0001171843-25-001532 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-18 | 2025-03-17 | ANIK | Colleran David | EVP, GC, Corp Sec | M - OptEx | $0.00 | +6,448 | 49.8K | +15% | $0 |
| D | 2025-03-18 | 2025-03-17 | ANIK | Colleran David | EVP, GC, Corp Sec | F - Tax | $15.91 | -1,893 | 48.0K | -4% | -$30.1K |
| D | 2025-03-18 | 2025-03-17 | ANIK | Colleran David | EVP, GC, Corp Sec | M - OptEx | $0.00 | -6,448 | 12.9K | -33% | $0 |
| DM | 2025-03-18 | 2025-03-14 | ANIK | Colleran David | EVP, GC, Corp Sec | A - Grant | $0.00 | +41.8K | 28.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-17 | M | A | 6,448 | $0.00 | 49,847 | D | — | — | (F1) Reflects the first vesting installment of RSUs granted on March 15, 2024, which the Company elected to settle in shares. |
| 2 | Common | Common Stock | 2025-03-17 | F | D | 1,893 | $15.91 | 47,954 | D | — | — | (F2) Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2025. (F3) Reflects the closing price of ANIK common stock on March 14, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. |
| 3 | Derivative | Restricted Stock Unit | 2025-03-17 | M | D | 6,448 | $0.00 | 12,897 | D | $0.00 · — to — | 6,448 Common Stock | (F6) Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. |
| 4 | Derivative | Restricted Stock Unit | 2025-03-14 | A | A | 13,669 | $0.00 | 13,669 | D | $0.00 · — to — | 13,669 Common Stock | (F5) Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 13,669 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold. |
| 5 | Derivative | Restricted Stock Unit | 2025-03-14 | A | A | 28,165 | $0.00 | 28,165 | D | $0.00 · — to — | 28,165 Common Stock | (F4) Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026. |